Difference in adverse-event profiles between mTOR inhibitors, temsirolimus, and everolimus for advanced renal cell carcinoma.
Masahiro Nozawa
No relevant relationships to disclose
Takashi Kikuchi
No relevant relationships to disclose
Mitsutoshi Nishimoto
No relevant relationships to disclose
Yasuyuki Kobayashi
No relevant relationships to disclose
Hirotsugu Uemura
No relevant relationships to disclose